|
Home > Argatroban & HIT Case Studies
Subacute Stent Thrombosis Associated with a Heparin-Coated
Stent and Heparin-Induced Thrombocytopenia.
Cruz D, et al. Cathet Cardiovasc Intervent 2003;58:80-83.
Catastrophic heparin-induced thrombocytopenia/thrombosis
syndrome related to the use of a Port-A-Cath in a breast cancer patient
receiving chemotherapy.
Dai M, Hsieh A, Chao T. Support Care Cancer (2004) 12:537-539.
Heparin-Induced Thrombocytopenia: A paradox of recognition
and treatment.
Matthai W. Contemporary Surgery Nov 2003;59(11):525-528.
Indications
Argatroban is indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia.
Argatroban is indicated as an anticoagulant in patients with or at risk for heparin-induced thrombocytopenia undergoing percutaneous coronary intervention (PCI).
Important Safety Information
As with all anticoagulants, bleeding is a serious concern. Argatroban is contraindicated in patients with overt major bleeding or those with hypersensitivity to the product or any of its components. Argatroban should be used with extreme caution in disease states or other circumstances in which there is an increased risk of hemorrhage. Overall major bleeding was reported in 5.3% of patients with HIT treated with Argatroban versus 6.7% of the historical controls. Overall major bleeding was reported in 1.8% of patients undergoing PCI treated with Argatroban versus 3.1% of the historical controls. Intracranial bleeding was not observed in the 568 patients treated with Argatroban for HIT (with or without thrombosis) or in the 91 patients who underwent PCI. The most common nonhemorrhagic side effects in HIT patients, regardless of the relationship to treatment, were dyspnea, hypotension, and fever. In patients undergoing PCI, the nonhemorrhagic side effects, regardless of the relationship to treatment, included chest pain, hypotension, and back pain. Please see full Prescribing Information for additional safety information on Argatroban.
|
